Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agenus. The associated price target remains the same with $23.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on several promising developments in Agenus’s clinical and regulatory landscape. The company has reported encouraging data from its Phase 1b pan-tumor trial, which demonstrated a significant overall survival benefit in patients with various types of cancer, including those who are refractory to standard treatments. This positive outcome is particularly notable in late-line populations where survival rates are typically lower.
Additionally, Agenus’s strategic partnership with Zydus is expected to provide substantial financial support, facilitating the initiation of the Phase 3 BATTMAN trial. The recent authorization for compassionate use of their treatment in France further underscores the potential for regulatory approval in broader markets. These factors collectively contribute to a favorable outlook for Agenus, justifying the Buy rating.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 5.9% and a 37.02% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Olema Pharmaceuticals, and Atossa Therapeutics.